ARTICLE | Company News
UroGenesys licenses antigen to Genentech
July 18, 2000 7:00 AM UTC
DNA acquired exclusive worldwide rights to develop antibody based therapeutics to treat cancer using UroGenesys' Prostate Stem Cell Antigen (PCSA), a cell surface protein with elevated expression in p...